Mallar Bhattacharya MD
Critical Care Medicine, Pleural Disease
Assistant Professor, Medicine, University of California, San Francisco, School of
Join to view full profile
505 Parnassus AveSan Francisco, CA 94143
Phone+1 415-476-6926
Dr. Bhattacharya is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 2007 - 2010
Johns Hopkins UniversityResidency, Internal Medicine, 2004 - 2007
Harvard Medical SchoolClass of 2004
Certifications & Licensure
CA State Medical License 2007 - 2028
American Board of Internal Medicine Critical Care Medicine- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- Cellular profiling identifies an early profibrotic alveolar type 2 cell signature in lung fibrosis.Ram P Naikawadi, Alexey Bazarov, Michael Wax Ii, Kaveh Boostanpour, Jasleen Kukreja
American Journal of Respiratory and Critical Care Medicine. 2026-06-01 - 1 citationsPrognostic Significance of Peripheral Blood Monocyte Count Among a National Cohort of Veterans with Pulmonary Fibrosis.Bhavika Kaul, Laura A Petersen, Harold R Collard, Peter Richardson, Ning Zhang
Annals of the American Thoracic Society. 2026-01-01 - 22 citationsMyeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis.Preeti Yadav, Javier Gómez Ortega, Prerna Dabral, Whitney Tamaki, Charles Chien
The Journal of Clinical Investigation. 2025-11-03
Press Mentions
Scientists Find Mechanism That Eliminates Senescent CellsMay 10th, 2021
Could Newly Found “Peacekeeping” Cells Be a Weapon Against COVID-19?March 27th, 2020
UCSF’s Resource Allocation Program (RAP) Accepting Applications for the Spring 2019 CycleFebruary 1st, 2019
Grant Support
- Purinergic Signaling in Fibroblast Activation and Lung FibrosisUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2025–2029
- Reverse electron transport inhibition to suppress fibroblast activation in agingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2025–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: